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Background: There is a clear link between irregular breathing and errors in medical imaging and radiation
treatment. The audiovisual biofeedback system is an advanced form of respiratory guidance that has previously
demonstrated to facilitate regular patient breathing. The clinical benefits of audiovisual biofeedback will be
investigated in an upcoming multi-institutional, randomised, and stratified clinical trial recruiting a total of 75 lung
cancer patients undergoing radiation therapy.
Methods/Design: To comprehensively perform a clinical evaluation of the audiovisual biofeedback system, a
multi-institutional study will be performed. Our methodological framework will be based on the widely used
Technology Acceptance Model, which gives qualitative scales for two specific variables, perceived usefulness and
perceived ease of use, which are fundamental determinants for user acceptance. A total of 75 lung cancer patients
will be recruited across seven radiation oncology departments across Australia. Patients will be randomised in a
2:1 ratio, with 2/3 of the patients being recruited into the intervention arm and 1/3 in the control arm. 2:1
randomisation is appropriate as within the interventional arm there is a screening procedure where only patients
whose breathing is more regular with audiovisual biofeedback will continue to use this system for their imaging
and treatment procedures. Patients within the intervention arm whose free breathing is more regular than
audiovisual biofeedback in the screen procedure will remain in the intervention arm of the study but their imaging
and treatment procedures will be performed without audiovisual biofeedback. Patients will also be stratified by
treating institution and for treatment intent (palliative vs. radical) to ensure similar balance in the arms across the
sites. Patients and hospital staff operating the audiovisual biofeedback system will complete questionnaires to
assess their experience with audiovisual biofeedback. The objectives of this clinical trial is to assess the impact of
audiovisual biofeedback on breathing motion, the patient experience and clinical confidence in the system, clinical
workflow, treatment margins, and toxicity outcomes.
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Discussion: This clinical trial marks an important milestone in breathing guidance studies as it will be the first
randomised, controlled trial providing the most comprehensive evaluation of the clinical impact of breathing
guidance on cancer radiation therapy to date. This study is powered to determine the impact of AV biofeedback
on breathing regularity and medical image quality. Objectives such as determining the indications and contra-
indications for the use of AV biofeedback, evaluation of patient experience, radiation toxicity occurrence and
severity, and clinician confidence will shed light on the design of future phase III clinical trials.
Trial registration: This trial has been registered with the Australian New Zealand Clinical Trials Registry (ANZCTR),
its trial ID is ACTRN12613001177741.
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RadiotherapyBackground
The precision of radiotherapy can be reduced due to
respiratory-related tumour motion, particularly for tu-
mours in the thoracic region, leading to increased ir-
radiation of healthy surrounding tissues, resulting in a
significant increase in radiation-related toxicity [1–3].
This is further exacerbated when respiration is irregular
in nature (deep/shallow breaths, baseline shifts, sus-
pended breathing, etc.) [4, 5]. A 1Gy increase in tumour
dose results in a 4 % improvement in survival, [6] how-
ever, a 0.5 cm range of tumour motion can cause a 4 ~
5 % variation in radiation dose [7] which leads to an in-
crease in mean dose to healthy surrounding tissues
resulting in an increase in risk of pneumonitis and radi-
ation toxicity [8, 9].
Techniques such as respiratory gating, breath-holds and
tumour tracking are clinically useful for tumour motion
management [10, 4, 11]. However, irregular respiration can
reduce the efficiency of such motion management tech-
niques, [12, 13] irregular respiration also causes motion ar-
tefacts and anatomic errors in medical imaging [14–19].
Breathing guidance is one such technique which spe-
cifically aims to produce regular patient breathing by
showing the patient how to adjust their breathing in
real-time. One such breathing guidance system is the au-
diovisual (AV) biofeedback system (shown in Fig. 1), de-
veloped by Venkat, et al [13].Fig. 1 AV biofeedback system (left). Display goggles and real-time position
display (right), as seen by the patient, of the AV biofeedback guiding interf
marker) in real timeAV biofeedback is a real-time, interactive and persona-
lised respiratory guide designed to facilitate regular patient
breathing. Table 1 outlines the findings from previous AV
biofeedback investigations.
However, none of the studies presented in Table 1 were
randomised trials, in addition to this, the findings of a re-
cent literature search yielded that a randomised clinical
trial with any breathing guidance intervention has not yet
been performed. To fill the gap in the literature, we have
designed a multi-institutional, phase II, randomised clin-
ical trial to thoroughly assess the clinical impact of the AV
biofeedback breathing guidance system. Based on previous
findings, we hypothesise that AV biofeedback will signifi-
cantly improve breathing regularity and reduce medical
imaging errors for lung cancer patients undergoing im-
aging and treatment procedures during radiotherapy.
This trial has been registered with the Australian New
Zealand Clinical Trials Registry (ANZCTR), its trial ID
is ACTRN12613001177741.
Methods/Design
This study aims to assess the clinical impact of AV biofeed-
back by recruiting 75 lung cancer patients across seven ra-
diation oncology departments. What follows is an outline
of the AV biofeedback setup, primary and secondary objec-
tives, participant selection criteria, the study workflow, and
statistical considerations for our study design.management (RPM) marker block on the abdomen shown. The visual
ace shows the waveguide (white curve) and a marker position (grey
Table 1 Details of previous AV biofeedback investigations
Investigation author (Year) Participants Findings
George [23] (2006) 24 lung cancer patients • Residual breathing motion within a gating window improved
Venkat [13] (2008) 10 healthy volunteers • Waveguide breathing guidance produced more regular breathing
than bar-model guidance and free breathing
Yang [22] (2012) Phantom study • 4D PET image quality improved
An [36] (2013) Retrospective analysis
of George (2006) data
• CTV coverage improved
• Internal motion variation improved
Kim, [21] Pollock, [37] &
Steel [38] (2012–2014)
15 healthy volunteers • Kim (2012): Breathing regularity of thoracic diaphragm and abdominal wall improved
• Pollock (2013): Accuracy of kernel density estimation motion prediction improved
• Steel (2014): Strong correlation between internal and external anatomic motion
for both AV biofeedback and free breathing
Lee [24] (2014) 5 healthy volunteers • Improved 3D MR image quality
• Reduced gated MRI scan time
Lu [39] (2014) 13 lung & liver cancer patients • Breathing regularity improved
• ITVMIP underestimated ITV10
Lee [40] (2014) 7 lung cancer patients • Improved intrafraction lung tumour motion consistency
• Improved interfraction lung tumour motion consistency
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The protocol for this clinical trial has been reviewed and
approved by the Hunter New England Human Research
Ethics Committee (HREC). This Human Research Ethics
Committee is constituted and operates in accordance with
the National Health and Medical Research Council’s
‘National Statement on Ethical Conduct in Human Re-
search (2007)’ (National Statement) and the ‘CPMP/ICH
Note of Guidance on Good Clinical Practice’. The Hunter
new England HREC has also been accredited by the New
South Wales Department of Health as a lead HREC under
the single ethical and scientific review. A report on the
progress of this clinical trial is required to be submitted
annually to the Hunter New England HREC.Audiovisual biofeedback system
The AV biofeedback system, as shown in Fig. 1, utilises
the Real-time Position Management system (RPM, Varian
Medical Systems, Palo Alto, USA) to track the motion of
an external marker positioned on the patient’s abdomen.
This real-time respiratory-motion is used by the AV bio-
feedback software to calculate an average cycle of respir-
ation (using a Fourier series fit from 10 obtained
respiratory cycles). This average cycle is used as the wave-
guide (white curve in Fig. 1) which continually moves
from right-to-left across the visual display and acts as part
of the visual prompt for AV biofeedback. Also on the vis-
ual display is a grey marker moving vertically up-and-
down corresponding to the anterior-posterior motion of
the marker block positioned on the patent’s abdomen. It is
the goal for the patient to keep the marker block withininhale-exhale limits (presented as the blue region in Fig. 1)
and match the grey marker block over the white wave-
guide. The audio component of AV biofeedback is clas-
sical music playing to the patient; the music fades to
silence should the marker block move outside the blue
area breathing limits. AV biofeedback has been shown to
be compatible in a number of imaging and treatment mo-
dalities, [20–22] as well as utilising different types of pa-
tient displays [23, 21, 24]. There are two options for
patient display in this study: video goggles, or a screen
mounted to the couch. Which patient display option is
utilised in this study will depend on what is available at
each institution.
Figure 2 illustrates the schematic of the AV biofeed-
back study setup, from the RPM camera monitoring pa-
tient breathing motion, to the AV biofeedback computer
receiving the RPM signal and extending the AV biofeed-
back guiding interface to the patient display.Objectives
This clinical trial will recruit 75 lung cancer patients
across 7 radiation oncology departments testing the fol-
lowing objectives:
Primary objective: In a prospective multi-institutional
randomised clinical trial we will test the hypothesis that
AV biofeedback will significantly improve breathing
regularity and reduce medical imaging errors for lung
cancer patients undergoing imaging and treatment pro-
cedures during radiotherapy.
Secondary objectives will involve patient-specific and
department-specific objectives:
Fig. 2 Audiovisual biofeedback study setup schematic
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AV biofeedback by:
1) Quantifying the proportion of patients for whom
breathing is more regular with AV biofeedback,
2) Quantifying the variability in breathing motion
throughout a course of treatment,
3) Quantifying the improvement in image quality with
AV biofeedback,
4) Evaluating the patient experience through a
perception of care survey,
5) Developing indications and contra-indications for
the use of AV biofeedback,
6) Quantifying the differences in image-guided radio-
therapy (IGRT) shifts during treatment, and
7) Recording toxicity outcomes for up to 12 months
after treatment has been completed.
Department-specific objectives are to evaluate the im-
pact of AV biofeedback on clinical testing by:
1) Quantifying any practice changes (e.g. margin
reduction),
2) Quantifying the impact on workflow using the AV
biofeedback device through time-motion studies,
3) Evaluating the operator and clinician confidence in
the AV biofeedback device’s reliability and clinical
efficacy through a technology-impact survey,
4) Quantifying the system robustness through
hardware and software fault reporting, and
5) Performing system quality assurance, sharing the
results through web-based uploads and provide
feedback for QA improvement.
Our methodological framework will be based on the
widely used Technology Acceptance Model (TAM)
[25, 26]. The TAM gives qualitative scales for two
specific variables, perceived usefulness and perceived
ease of use, which are fundamental determinants for
user acceptance.Study participant selection criteria
This study will recruit patients with cancer of the lung
receiving external beam radiation therapy. Patients fit-
ting the eligibility criteria (see below) will be identified
and introduced to this study by their treating physicians,
who will participate as investigators in this study. The
eligibility criteria are as follows:
1) Lung cancer patients
i. No restrictions to type of external beam radiation
therapy being received
ii. Primary or secondary cancer
2) >18 years old
3) No gender or ethnic restrictions
4) An ECOG score in the range of 0 to 2
5) Able to give written informed consent and
willingness to participate and comply with the study
6) No pregnant / lactating woman
Study workflow
Once informed consent has been obtained, the patient will
be randomised into either the intervention or control arm
of the study. For patients randomised into the intervention
arm, prior to their planning and treatment they will
undergo a breathing decision session during which they will
breathe both with and without the guidance of AV biofeed-
back. Preceding each breathing session will be a training
session to familiarise the patient with the AV biofeedback
system. After the breathing decision session has been com-
pleted, the most reproducible breathing condition (AV bio-
feedback or free breathing) will be determined in situ by an
‘Analyse Respiratory Session’ function within the AV bio-
feedback software. It will be the most reproducible breath-
ing condition that will continue to be used throughout the
rest of that particular patient’s planning and treatment. The
flowchart for this study is shown in Fig. 3.
For all patients, each follow-up visitation they have
with their treating physician for the first 12 months after
their treatment has finished, their treating physician will
Fig. 3 Study flowchart
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Patient-Specific Objective 7: Recording toxicity out-
comes for up to 12 months after treatment has been
completed by reporting the occurrence and severity of
any radiation toxicities.
Patient randomisation
This trial is stratified, hence, study group random alloca-
tion will be determined by minimisation [27, 28]. Patients
will be stratified by treating institution and for treatment
intent (palliative vs. radical) and minimisation consider-
ably reduces the imbalance of these stratification factors
across the control and intervention groups of the study.
Patients will be randomised in a 2:1 ratio, 2 out of 3 pa-
tients will be randomised into the AV biofeedback (inter-
vention) arm and 1 out of 3 will be randomised into the
free breathing (control) arm as illustrated by Fig. 3.
Sample size and power calculation
The statistical considerations for this study are largely
based on a previous study conducted at Virginia Com-
monwealth University (VCU) on 24 lung cancer patients
[23, 29]. Prior to this multi-institutional clinical trial, the
VCU study was the largest AV biofeedback investigation,
recruiting a total of 26 lung cancer patients, however, 2
patients dropped out due to not being treated with
radiotherapy or rapid worsening of disease, and so theirdata was not collected. In the VCU study 109 breathing
sessions were performed comparing AV biofeedback to
free breathing, of which, 87 sessions (80 %) demon-
strated more regular breathing with AV biofeedback.
Framing this is in a more clinical relevant way: irregular
breathing motion exacerbates the systematic errors (Σ)
arising from motion image artefacts and variations be-
tween the planned and treated anatomy, as well as ran-
dom errors (σ) from day-to-day variations in the treated
anatomy [30, 15, 31]. To combine systematic and ran-
dom errors and estimate the margin contribution due to
breathing irregularity we will use the van Herk method
[32]: margin = 2.5Σ + 0.7σ, incorporating the respiratory
components of systematic and random errors. A clinic-
ally significant difference in clinical improvement due to
AV biofeedback has been determined to be a margin cal-
culation of less than 5 mm. This magnitude of reduction
was elected as clinically significant because this is the
same magnitude of displacement attributed to contribut-
ing to significant artefacts and errors during radiother-
apy procedures as detailed in AAPM Task Group 76 [4].
From this van Herk calculation, in the VCU study there
were 14/24 patients with margins <5 mm with AV bio-
feedback, while only 5/24 for free breathing.
In this proposed study, to get a more accurate indica-
tion of the proportion of patients with reduced margins
calculated using the van Herk method we have designed
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the potential impact of an AV biofeedback system in
regulating breathing in patients receiving radiation
therapy for the treatment of lung cancer. Without the
AV biofeedback system, it is conservatively estimated
that approximately 40 % of patients naturally exhibit
regular breathing (margin component below 5 mm). In-
creasing this proportion to 60 % using the AV biofeed-
back system would be clinically worthwhile. Based on
Simon’s design, [33] a sample size of 50 patients receiv-
ing the AV biofeedback system will have at least 80 %
power with 95 % confidence to rule out a regular rate
of 40 % in favour of a 60 % rate. To minimise patient
selection bias and provide an estimate of regular
breathing from a contemporary control, the proposed
design will be a randomised phase II with a 50 patients
receiving the intervention and 25 receiving current
standard of care. Patients will be randomised in a 2:1
ratio, with 2/3 of the patients being recruited into the
AV biofeedback (intervention) arm and 1/3 in the free
breathing (control) arm as illustrated by Fig. 3. 2:1 ran-
domisation is appropriate as within the interventional
arm there is a screening procedure where only patients
whose breathing is more regular with AV biofeedback
use this system for their imaging and treatment proce-
dures. Patients will be stratified by treating institution
and for treatment intent (palliative vs. radical) to ensure
similar balance in the arms across the sites. As the study
is not powered for formal comparisons between the
groups, estimates of the proportion of patients which do
not experience irregular breathing will provide informa-
tion as to whether further investigation is warranted.
Assuming a contamination and dropout rate of no
more than 10 %, this study will require that 75 + 8 = 83
patients be recruited (the 10 % value was based on the
2/26 patient drop-out rate in the VCU study).
Patients at each institution will be treated per depart-
ment protocol with no additional constraints on dose,
fractionation, immobilisation or image guided procedures.Fig. 4 Example of breathing motion trace (left) then separated into individual cyResults will be adjusted for institution (using a fixed effect)
to account for differences between institutions.
Data analysis
The primary objective is to assess the impact of AV
biofeedback on breathing regularity and image errors;
the section that follows details the metrics to be utilised
for the primary objective.
Breathing motion regularity is quantified as the root
mean square error (RMSE) in displacement and period
[13, 21, 24, 34]. A breathing signal is separated into its
individual cycles and an ‘average’ waveform is calcu-
lated using a Fourier series fit. Figure 4 illustrates an
example breathing trace, its separation into cycles, and
its average waveform.
RMSE will be calculated as detailed by Venkat, et al.,
(2008),[13] but will be outlined here for clarity. For a
breathing pattern comprised of n individual breathing
cycles, where each cycle in the phase domain can be
written as X = {x1, x2,…, x360} and the average waveform
of these cycles can be written as Y = {y1, y2,…, y360}, the
RMSE in displacement is calculated as:








The period of each of the n breathing cycles, in seconds,
can be written as P = {p1, p2,…, pn}, with the period of the
average waveform expressed as Periodmean, the RMSE in
period is calculated as:






The impact of AV biofeedback on 4D-CT image qual-
ity will utilise an automated method of image artefact
identification developed by Cui, et al., (2012), [35] but
will be outlined here for clarity. The method is based oncles with the average waveform shown as the red dashed curve (right)
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tions A and B; the edge similarity between slice A and
slice B is expressed by the normalised correlation coeffi-
cient (NCC). Deviations from standard NCC, represent-
ing normal anatomical changes between edge slices,
signify the presence of an image artefact. Cui, et al.,
(2012) reported good agreement of their method with
the assessment of two observers.
Discussion
This clinical trial marks an important milestone in breath-
ing guidance studies as it will be the first randomised, con-
trolled trial providing the most comprehensive evaluation
of the clinical impact of breathing guidance on cancer ra-
diation therapy to date. Based on the structure of previous
investigations, and taking into consideration the increase
in scope of this study, the authors have designed a multi-
institutional, randomised, phase II, stratified clinical trial
to test the hypothesis that audiovisual biofeedback breath-
ing guidance will significantly improve breathing regular-
ity and reduce medical imaging errors for lung cancer
patients undergoing imaging and treatment procedures
during radiotherapy. While patients will be stratified by
treating institution and for treatment intent, the study is
not powered for formal comparisons between the these
stratified groups; estimates from the current proposed
study of the proportion of patients which do not experi-
ence irregular breathing will provide information as to
whether further investigation is warranted. Further to this,
objectives such as determining the indications and contra-
indications for the use of audiovisual biofeedback, evalu-
ation of patient experience, radiation toxicity occurrence
and severity, and clinician confidence will shed light on
the design of future phase III clinical trials.
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